ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014
December 22 2014
ConvaTec, a privately-held medical products and technologies company, today announced that Paul Moraviec has been appointed Interim Chief Executive Officer of the company, effective December 22, 2014.
Mr. Moraviec succeeds Ken Berger. "The Board of Directors of ConvaTec thanks Mr. Berger for his service in leading ConvaTec over the past three years," said Magnus Lundberg, the Chairman of ConvaTec's Board of Directors. "We are confident that the company is well positioned for the future." The company has begun the process to identify a permanent CEO.
Mr. Moraviec joined ConvaTec in 2009 as President, Europe, Middle East and Africa, which is the company's largest geographic region. Based in Schaffhausen, Switzerland, Mr. Moraviec has a track record of driving growth in major global healthcare companies across a number of medical device specialties including orthopedics, neurosurgery and general surgery.
Mr. Moraviec has held international leadership roles with Johnson & Johnson, Abbott Laboratories and Bausch and Lomb, as well as CEO roles with two early stage venture capital funded companies.
ConvaTec is a global medical products and technologies company, with leading market positions in wound therapeutics, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. ConvaTec has over 8,000 employees, with 11 manufacturing sites in 8 countries, and we do business in more than 100 countries. We are owned by Nordic Capital and Avista Capital Partners. More information is available at www.convatec.com.